How researchers are overcoming the challenges of oral peptide bioavailability, including absorption enhancers, enteric coatings, and nanoparticle systems.
Filed under evidence research, written for researcher, pharmacist-compounder, investor, evidence level B.
Not medically reviewed. Last updated 2026-03-30. Nothing here is medical advice.
Oral delivery of peptides has been a long-standing challenge in pharmaceutical science. Peptides are typically degraded by gastrointestinal enzymes and poorly absorbed through the intestinal epithelium. Recent technological advances are changing this landscape.
Oral semaglutide (Rybelsus) uses sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) to enhance absorption. SNAC creates a local pH change and transiently increases permeability in the stomach.
Protect peptides from stomach acid and release them in the small intestine where pH is more favorable.
Compounds that transiently open tight junctions between intestinal epithelial cells to allow paracellular peptide absorption.
Lipid nanoparticles, polymeric nanoparticles, and self-emulsifying systems that protect peptides and enhance uptake.
Formulations that adhere to the intestinal mucosa, prolonging contact time and improving absorption.
Oral semaglutide (Rybelsus) was a breakthrough, demonstrating that oral peptide delivery is commercially viable. However, oral bioavailability remains low (~1%) and requires specific dosing conditions (fasting, minimal water).
This article provides drug delivery science education.
More guides: All guides, Safety centre, Peptide library.